image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - GB
$ 10.625
4.37 %
$ 48.5 B
Market Cap
26.56
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one HLN stock under the worst case scenario is HIDDEN Compared to the current market price of 10.6 USD, Haleon plc is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one HLN stock under the base case scenario is HIDDEN Compared to the current market price of 10.6 USD, Haleon plc is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one HLN stock under the best case scenario is HIDDEN Compared to the current market price of 10.6 USD, Haleon plc is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
11.3 B REVENUE
4.09%
2 B OPERATING INCOME
9.37%
1.11 B NET INCOME
-0.71%
2.1 B OPERATING CASH FLOW
1.79%
-134 M INVESTING CASH FLOW
98.47%
-1.57 B FINANCING CASH FLOW
-22.69%
2.78 B REVENUE
-4.93%
496 M OPERATING INCOME
-25.08%
303 M NET INCOME
-28.37%
0 OPERATING CASH FLOW
0.00%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Haleon plc
image
Current Assets 4.82 B
Cash & Short-Term Investments 1.04 B
Receivables 1.35 B
Other Current Assets 2.42 B
Non-Current Assets 29.2 B
Long-Term Investments 65 M
PP&E 1.9 B
Other Non-Current Assets 27.3 B
Current Liabilities 4.64 B
Accounts Payable 1.86 B
Short-Term Debt 656 M
Other Current Liabilities 2.13 B
Non-Current Liabilities 12.7 B
Long-Term Debt 8.8 B
Other Non-Current Liabilities 3.89 B
EFFICIENCY
Earnings Waterfall Haleon plc
image
Revenue 11.3 B
Cost Of Revenue 4.34 B
Gross Profit 6.96 B
Operating Expenses 4.96 B
Operating Income 2 B
Other Expenses 885 M
Net Income 1.11 B
RATIOS
59.70% GROSS MARGIN
59.70%
17.66% OPERATING MARGIN
17.66%
9.28% NET MARGIN
9.28%
6.32% ROE
6.32%
3.08% ROA
3.08%
4.53% ROIC
4.53%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Haleon plc
image
Net Income 1.11 B
Depreciation & Amortization 309 M
Capital Expenditures -336 M
Stock-Based Compensation 76 M
Change in Working Capital -107 M
Others 585 M
Free Cash Flow 1.76 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Haleon plc
image
Wall Street analysts predict an average 1-year price target for HLN of $9.68 , with forecasts ranging from a low of $9.15 to a high of $10.2 .
HLN Lowest Price Target Wall Street Target
9.15 USD -13.88%
HLN Average Price Target Wall Street Target
9.68 USD -8.94%
HLN Highest Price Target Wall Street Target
10.2 USD -4.00%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.0514 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Haleon plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Haleon to invest $54 mln in US R&D centre to boost product innovation Consumer healthcare company Haleon said on Wednesday it will invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovations. reuters.com - 1 month ago
AHCO vs. HLN: Which Stock Is the Better Value Option? Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Haleon PLC Sponsored ADR (HLN). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 1 month ago
Pfizer to further reduce stake in Haleon through share sale Pfizer Inc (NYSE:PFE, ETR:PFE) plans to sell around 700 million shares of Haleon PLC (LSE:HLN, NYSE:HLN), representing a 7.7% stake, via a secondary offering through an accelerated book-building process targeting institutional investors. Currently holding 15% of the Panadol maker, Pfizer expects to reduce its interest to about 7.3 per cent upon completion. proactiveinvestors.co.uk - 1 month ago
Pfizer Sells 700 Million Haleon Shares for $3 Billion The sale decreases Pfizer's shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%. wsj.com - 1 month ago
Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner Pfizer intends to sell about 700 million ordinary shares in Haleon , cutting its stake to about 7.3% in the British consumer healthcare group, a bookrunner said on Tuesday. reuters.com - 1 month ago
TUMS Teams Up with DraftKings to Launch TUMS Fantasy Foodball Pool, Making Gameday Food Dreams a Reality Fans can draft their top food and drink picks for a free shot at  winning a share of $40,000 in total cash prizes WARREN, N.J. , Jan. 9, 2025 /PRNewswire/ -- As hundreds of millions prepare to tune into the biggest day in football, a new survey from TUMS has revealed that 1 in 4 viewers will be focused on the real MVP: the food. prnewswire.com - 1 month ago
Haleon: Guidance Implies Uncertainty Around Flu Season Haleon plc is logging solid organic performances led by their solid brand portfolio for oral health with brands like Sensodyne and Parodontax. This is despite some tough comps still in the results, particularly in VMS. Guidance remains around the 4-6% organic growth figure, ignoring FX effects, despite the momentum in the Q3. seekingalpha.com - 2 months ago
Haleon Welcomes Joe Sta-Romana as Chief Customer Officer to Lead US Growth and Transformation WARREN, N.J. , Dec. 2, 2024 /PRNewswire/ -- Haleon, a world-leading consumer health company, is pleased to announce the appointment of Joe Sta-Romana as Chief Customer Officer (CCO) for its US business, effective December 1, 2024. prnewswire.com - 3 months ago
Dividend Income: Lanny's October 2024 Summary Big Oil with BHP Billiton came big with a massive dividend. Canadian Imperial, one of the big 6 Canadian banks, sent a massive $210 dividend my way. There are a few less names now in 2024 than 2023, such as MDU Resources and Haleon. seekingalpha.com - 3 months ago
Haleon Selects Vistar Media as Preferred Global Partner for Programmatic Out-of-Home (OOH) Advertising Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy globenewswire.com - 3 months ago
Haleon plc (HLN) Q3 2024 Sales Call Transcript Haleon plc (NYSE:HLN ) Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ET Company Participants Rakesh Patel - Director of Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Group AG David Hayes - Jefferies Group LLC Iain Simpson - Barclays Rashad Kawan - Morgan Stanley Celine Pannuti - JPMorgan Chase & Co. Victoria Petrova - BofA Securities Karel Zoete - Kepler Cheuvreux Tom Sykes - Deutsche Bank Rakesh Patel Good morning everyone, and welcome to Haleon's Conference Call for our Third Quarter Trading Statement. I am Rakesh Patel, Director, Investor Relations, and with me today is Tobias Hestler, our CFO. seekingalpha.com - 3 months ago
Panadol maker Haleon takes hit from currency headwinds Currency fluctuations meant Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100-listed Panadol and Sensodyne owner, saw year-on-year reported revenue by 0.6% to £2.78 billion in the third quarter. Stripping away the impact of the weaker US dollar, the consumer health giant's organic revenues increased by 6.1%. proactiveinvestors.co.uk - 4 months ago
8. Profile Summary

Haleon plc HLN

image
COUNTRY GB
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 48.5 B
Dividend Yield 0.00%
Description Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Contact Building 5, Weybridge, KT13 0NY https://www.haleon.com
IPO Date July 25, 2022
Employees 25408
Officers Mr. Brian James McNamara Chief Executive Officer & Executive Director Ms. Claire Dickson Chief Digital & Technology Officer Ms. Dawn Amanda Allen Chief Financial Officer & Director